The long-term objective of the Pharmacology Shared Resource is to provide critical pharmacologic support, services and expertise for Cancer Center investigators engaged in the development and evaluation of anticancer agents.
The specific aims of the Shared Resource are to provide the necessary services and expertise for: 1) the conduct of clinical pharmacokinetic studies performed through the vigorous NCI-funded Phase I and Phase II clinical trials programs in the Cancer Center, 2) for the conduct of pharmacogenetic studies performed in conjunction with appropriate early clinical trials and 3) for the conduct of preclinical pharmacology studies in support of Cancer Center investigator research. To accomplish these aims, the Shared Resource has state of the art capabilities and expertise for the sensitive and specific analysis of drugs and their metabolites in biological specimens, for structure elucidation and pharmacologic characterization of drug metabolites, for the conduct of clinical and preclinical pharmacokinetic studies using those assay methodologies, for the detailed analysis of pharmacokinetic data and for the conduct of pharmacogenetic studies using validated assays for determination of allelic variants of genes related to drug response. In addition, Shared Resource key personnel consult with Cancer Center investigators in the design of studies and the analysis and interpretation of pharmacologic data obtained in those studies. During the current funding period, the Shared Resource has conducted approximately 30 clinical pharmacology protocol-based studies in conjunction with Phase I and Phase II clinical trials encompassing pharmacokinetic and pharmacogenetic components. The Shared Resource also provided preclinical pharmacologic support for eight Cancer Center investigator-initiated laboratory projects either for grantfunded studies or in preparation for grant submissions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-37
Application #
8320363
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
37
Fiscal Year
2011
Total Cost
$243,733
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications